About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Fractyl Health, Inc. - Common Stock (NQ:GUTS)

0.7081 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Fractyl Health, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance ↗
Fractyl Health (NASDAQ:GUTS) outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain... 
Via MarketBeat
News headline image
Deadline Approaching: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith
From Law Offices of Howard G. Smith
Via Business Wire
Fractyl Health Inc (NASDAQ:GUTS) Q1 Earnings: Net Income Swing Masks Core Operating Burn as Key Revita Data Readout Looms ↗
Via Chartmill
News headline image
Deadline Alert: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Deadline Soon: Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
Law Offices of Howard G. Smith Encourages Fractyl Health, Inc. (GUTS) Shareholders To Inquire About Securities Fraud Class Action
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Law Offices of Frank R. Cruz Encourages Fractyl Health, Inc. (GUTS) Shareholders to Inquire About Securities Fraud Class Action
From Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Securities Fraud Investigation Into Fractyl Health, Inc. (GUTS) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay Wolke & Rotter LLP
Via Business Wire
News headline image
Faruqi & Faruqi, LLP Urges Fractyl Health, Inc. (NASDAQ: GUTS) Investors to Seek Counsel Before the October 20, 2026 Lead Plaintiff Deadline in the Securities Class Action
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Fractyl Health, Inc. (GUTS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
Securities Fraud Investigation Into Fractyl Health, Inc. (GUTS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
Stockholder Alert: Robbins LLP Informs Investors of the Fractyl Health, Inc. Class Action
From Robbins LLP
Via Business Wire
News headline image
Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Eyes Q4 Revita Data, Launches Rejuva Gene Therapy Trial ↗
Fractyl Health (NASDAQ:GUTS) is advancing two one-time treatment approaches intended to provide durable benefits for obesity, type 2 diabetes and related metabolic diseases, Chief Executive Officer... 
Via MarketBeat
News headline image
Fractyl Health Q2 Earnings Call Highlights ↗
Fractyl Health (NASDAQ:GUTS) said its Revita endoscopic procedure showed durable weight-maintenance results one year after patients discontinued GLP-1 therapy, while the company reaffirmed plans to... 
Via MarketBeat
Topics Earnings
News headline image
Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Participate in Upcoming Investor Events
From Fractyl Health, Inc.
Via GlobeNewswire
These stocks are moving in today's session ↗
Via Chartmill
News headline image
Fractyl Health Says Revita Helped Patients Keep Weight Off After Stopping GLP-1s ↗
Fractyl Health (NASDAQ:GUTS) reported one-year data from the randomized midpoint cohort of its REMAIN-1 study, saying its Revita procedure helped patients maintain a larger share of GLP-1-induced... 
Via MarketBeat
News headline image
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Reports Positive One-Year REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Appoints Mike Zumdahl as Senior Vice President, Market Access and Commercial Strategy
Experienced market access leader joins to build reimbursement and health economic infrastructure for Revita® ahead of anticipated REMAIN-1 Pivotal Cohort topline data in early Q4 2026 
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Q1 Earnings Call Highlights ↗
Fractyl Health (NASDAQ:GUTS) said it remains on track to report pivotal data for its Revita therapy in early fourth quarter 2026, as management highlighted clinical, regulatory and reimbursement... 
Via MarketBeat
Topics Earnings
News headline image
Fractyl Health Reports First Quarter 2026 Financial Results and Business Updates
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health Authorized to Initiate First-in-Human Trial of RJVA-001 in the Netherlands: First Gene Therapy Candidate to Enter Clinical Development for Type 2 Diabetes
From Fractyl Health, Inc.
Via GlobeNewswire
News headline image
Fractyl Health to Report First Quarter 2026 Financial Results and Provide Business Updates on May 12, 2026, and Will Participate in an Upcoming Investor Conference
From Fractyl Health, Inc.
Via GlobeNewswire
What's going on in today's after hours session ↗
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.